T1	Participants 121 129	patients
T2	Participants 608 651	double-blind, randomized, multicenter study
T3	Participants 123 172	tients with senile dementia of the Alzheimer type
T4	Participants 863 922	patients with mild to moderate probable Alzheimer's disease
T5	Participants 935 981	204 patients with probable Alzheimer's disease
T6	Participants 1020 1214	136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis
T7	Participants 1456 1491	better outcome in the placebo group
T8	Participants 2087 2096	tolerated
